Cyclic nucleotide phosphodiesterase (PDE) inhibitors: Novel therapeutic agents for progressive renal disease

Experimental Biology and Medicine

Volumn 232, Issue 1, 2007, Pages 38-51

  Cheng, Jingfei ^a   Grande, Joseph P ^a  

^a Mayo Clinic   (United States)

Author keywords

cAMP; cGMP; Phosphodiesterase; Progressive renal disease

Indexed keywords

1 [6 CHLORO 4 (3,4 METHYLENEDIOXYBENZYLAMINO) 2 QUINAZOLINYL] 4 PIPERIDINECARBOXYLIC ACID; 2 METHYL 5 NITROBENZENESULFONIC ACID DIMETHYLAMIDE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; CILOMILAST; CILOSTAMIDE; CILOSTAZOL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DENBUFYLLINE; DIPYRIDAMOLE; LIXAZINONE; MILRINONE; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; NICARDIPINE; PAPAVERINE; PENTOXIFYLLINE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VII INHIBITOR; ROFLUMILAST; ROLIPRAM; SILDENAFIL; TADALAFIL; THIADIAZOLE DERIVATIVE; UNINDEXED DRUG; VARDENAFIL; VINPOCETINE; ZAPRINAST;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DRUG MECHANISM; ENZYME STRUCTURE; GLOMERULONEPHRITIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; MITOGENESIS; NEPHROTIC SYNDROME; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CYCLIC AMP; CYCLIC GMP; KIDNEY; KIDNEY DISEASES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 33846129423     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (162)

1. Houslay MD. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 69:249-315, 2001.
2. Dousa T. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 55:29-62, 1999.
3. Dousa T. Signaling role of PDE isozymes in pathobiology of glomerular mesangial cells: studies in vitro and in vivo. Cell Biochem Biophys 29:19-34, 1998.
4. Cheng J, Thompson MA, Walker HJ, Gray CE, Diaz Encarnacion MM, Warner GM, Grande JP. Differential regulation of mesangial cell mitogenesis by cAMP phosphodiesterase isozymes 3 and 4. Am J Physiol Renal Physiol 287:F940-F953, 2004.
5. Cheng J, Diaz Encarnacion MM, Warner GM, Gray CE, Nath KA, Grande JP. TGF-beta1 stimulates monocyte chemoattractant protein-1 expression in mesangial cells through a phosphodiesterase isoenzyme 4-dependent process. Am J Physiol Cell Physiol 289:C959-C970, 2005.
6. Offermanns S. In vivo functions of heterotrimeric G-proteins: studies in Galpha deficient mice. Oncogene 20:1635-1642, 2001.
7. Beavo JA, Brunton LL. Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol 3:710-718, 2002.
8. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52:375-414, 2000.
9. de Rooij J, Zwartkruis F, Verheijen M, Cool R, Nijman S, Wittinghofer A, Bos J. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396:474-477, 1998.
10. Kawasaki H, Springett G, Mochizuke N, Toki S, Nakaya M, Matsuda M, Housman D, Graybiel A. A family of cAMP-binding proteins that directly activate Rap1. Science 282:2275-2279, 1998.
11. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84:137-167, 2004.
12. Tasken K, Skalhegg BS, Tasken KA, Solberg R, Knutsen HK, Levy FO, Sandberg M, Orstavik S, Larsen T, Johansen AK, Vang T, Schrader HP, Reinton NT, Torgersen KM, Hansson V, Jahnsen T. Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res 31:191-204, 1997.
13. McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, van Heeke G, Houslay MD. In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal 17: 1158-1173, 2005.
14. Michel JJ, Scott JD. AKAP mediated signal transduction. Annu Rev Pharmacol Toxicol 42:235-257, 2002.
15. Colledge M, Scott JD. AKAPs: from structure to function. Trends Cell Biol 9:216-221, 1999.
16. Rubin CS. A kinase anchor proteins and the intracellular targeting of signals carried by cyclic AMP. Biochim Biophys Acta 1224:467-479, 1994.
17. Diviani D, Scott JD. AKAP signaling complexes at the cytoskeleton. J Cell Sci 114:1431-1437, 2001.
18. Rich TC, Fagan KA, Tse TE, Schaack J, Cooper DM, Karpen JW. A uniform extracellular stimulus triggers distinct cAMP signals in different compartments of a simple cell. Proc Natl Acad Sci U S A 98: 13049-13054, 2001.
19. Ponsioen B, Zhao J, Riedl J, Zwartkruis F, van der Krogt G, Zaccolo M, Moolenaar WH, Bos JL, Jalink K. Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. EMBO Rep 5:1176-1180, 2004.
20. Laroche-Joubert N, Marsy S, Michelet S, Imbert-Teboul M, Doucet A. Protein kinase A-independent activation of ERK and H,K-ATPase by cAMP in native kidney cells: role of Epac I. J Biol Chem 277:18598-18604, 2002.
21. Jurevicius J, Fischmeister R. cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists. Proc Natl Acad Sci U S A 93:295-299, 1996.
22. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 295: 1711-1715, 2002.
23. Zaccolo M, Cesetti T, Di Benedetto G, Mongillo M, Lissandron V, Terrin A, Zamparo I. Imaging the cAMP-dependent signal transduction pathway. Biochem Soc Trans 33:1323-1326, 2005.
24. Lissandron V, Terrin A, Collini M, D'Alfonso L, Chirico G, Pantano S, Zaccolo M. Improvement of a FRET-based indicator for cAMP by linker design and stabilization of donor-acceptor interaction. J Mol Biol 354:546-555, 2005.
25. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52, 2001.
26. Mehats C, Andersen CB, Filopanti M, Jin SL, Conti M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 13:29-35, 2002.
27. Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 66:241-277, 2001.
28. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157:351-370, 1998.
29. Conti M, Jin SL. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63:1-38, 1999.
30. Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12: 174-179, 2000.
31. Degerman E, Belfrage P, Manganiello V. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 272:6823-6826, 1997.
32. Perry MJ, Higgs GA. Chemotherapeutic potential of phosphodiesterase inhibitors. Curr Opin Chem Biol 2:472-481, 1998.
33. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18, 2003.
34. Houslay MD, Sullivan M, Bolger GB. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol 44:225-342, 1998.
35. Nyby MD, Hori MT, Ormsby B, Gabrielian A, Tuck ML. Eicosapentaenoic acid inhibits Ca2+ mobilization and PKC activity in vascular smooth muscle cells. Am J Hypertens 16:708-714, 2003.
36. Houslay M, Milligan G. Tailoring cAMP signalling responses through isoform multiplicity. Trends Pharmacol Sci 22:217-224, 1997.
37. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T, Houslay MD, Zaccolo M. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 95:67-75, 2004.
38. Manganiello V, Elks M. Regulation of particulate cAMP phosphodiesterase activity in 3T3-L1 adipocytes: the role of particulate phosphodiesterase in the antilipolytic action of insulin. In: Belfrage P, Donner J, Stralfors P, Eds. Mechanisms of Insulin Action. New York: Elsevier Science Publishers, pp147-166, 1986.
39. Chini CCS, Grande JP, Chini EN, Dousa TP. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis. J Biol Chem 272:9854-9859, 1997.
40. Elks ML, Manganiello VC. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3′,5′- monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes. Endocrinology 115:1262-1268, 1984.
41. Scotland G, Beard M, Erdogan S, Huston E, McCallum F, MacKenzie S, Peden A, Pooley L, Rena N, Ross A, Yarwood S, Houslay M. Intracellular compartmentalization of PDE4 cyclic AMP-specific phosphodiesterases. Methods 14:65-79, 1998.
42. Dodge KL, Khouangsathiene S, Kapiloff MS, Mouton R, Hill EV, Houslay MD, Langeberg LK, Scott JD. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J 20:1921-1930, 2001.
43. MacKenzie SJ, Houslay MD. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element- binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem J 347:571-578, 2000.
44. Elks ML, Manganiello VC. Antilipolytic action of insulin: role of cAMP phosphodiesterase activation. Endocrinology 116:2119-2121, 1985.
45. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, Zaccolo M. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 98:226-234, 2006.
46. Rochais F, Vandecasteele G, Lefebvre F, Lugnier C, Lum H, Mazet JL, Cooper DM, Fischmeister R. Negative feedback exerted by cAMP-dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes: an in vivo study using adenovirus-mediated expression of CNG channels. J Biol Chem 279:52095-52105, 2004.
47. Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, van Heeke G, Houslay MD. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem 280:33178-33189, 2005.
48. Lerner A, Epstein PM. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J 393:21-41, 2006.
49. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503-1519, 2005.
50. Bolger G, Michaeli T, Martins T, St John T, Steiner B, Rodgers L, Riggs M, Wigler M, Ferguson K. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 13:6558-6571, 1993.
51. Millen J, MacLean MR, Houslay MD. Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells. Eur J Cell Biol 85:679-691, 2006.
52. Baillie GS, Houslay MD. Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr Opin Cell Biol 17: 129-134, 2005.
53. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493-5496, 2003.
54. Shakur Y, Takeda K, Kenan Y, Yu ZX, Rena G, Brandt D, Houslay MD, Degerman E, Ferrans VJ, Manganiello VC. Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J Biol Chem 275: 38749-38761, 2000.
55. McPhee I, Yarwood S, Scotland G, Huston E, Beard M, Ross A, Houslay E, Houslay M. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. J Biol Chem 274:11796-11810, 1999.
56. Bolger GB, Baillie GS, Li X, Lynch MJ, Herzyk P, Mohamed A, Mitchell LH, McCahill A, Hundsrucher C, Klussmann E, Adams DR, Houslay MD. Scanning peptide array analyses identify overlapping binding sites for the signaling scaffold proteins, betaarrestin and RACK1 in the cAMP-specific phosphodiesterase, PDE4D5. Biochem J 398:23-26, 2006.
57. Yarwood SJ, Steele MR, Scotland G, Houslay MD, Bolger GB. The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol Chem 274:14909-14917, 1999.
58. Verde I, Pahlke G, Salanova M, Zhang G, Wang S, Coletti D, Onuffer J, Jin SL, Conti M. Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem 276:11189-11198, 2001.
59. Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS, Houslay MD. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem 278:33351-33363, 2003.
60. Tasken KA, Collas P, Kemmner WA, Witczak O, Conti M, Tasken K. Phosphodiesterase 4D and protein kinase A type II constitute a signaling unit in the centrosomal area. J Biol Chem 276:21999-22002, 2001.
61. Jeon YH, Heo YS, Kim CM, Hyun YL, Lee TG, Ro S, Cho JM. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 62:1198-1220, 2005.
62. Scapin G, Patel SB, Chung C, Varnerin JP, Edmondson SD, Mastracchio A, Parmee ER, Singh SB, Becker JW, Van der Ploeg LH, Tota MR. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry 43: 6091-6100, 2004.
63. Zhang KY, Card GL, Suzuki Y, Artis DR, Fong D, Gillette S, Hsieh D, Neiman J, West BL, Zhang C, Milburn MV, Kim SH, Schlessinger J, Bollag G. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 15:279-286, 2004.
64. Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 12:2233-2247, 2004.
65. Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 23:201-207, 2005.
66. MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, Houslay MD. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J Biol Chem 275:16609-16617, 2000.
67. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, Houslay MD. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J 18: 893-903, 1999.
68. Liu H, Palmer D, Jimmo SL, Tilley DG, Dunkerley HA, Pang SC, Maurice DH. Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. J Biol Chem 275:26615-26624, 2000.
69. Baillie G, MacKenzie SJ, Houslay MD. Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). Mol Pharmacol 60:1100-1111, 2001.
70. Baillie GS, MacKenzie SJ, McPhee I, Houslay MD. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol 131:811-819, 2000.
71. Houslay MD, Baillie GS. The role of ERK2 docking and phosphorylation of PDE4 cAMP phosphodiesterase isoforms in mediating cross-talk between the cAMP and ERK signalling pathways. Biochem Soc Trans 31:1186-1190, 2003.
72. Hill EV, Houslay MD, Baillie GS. Investigation of extracellular signal-regulated kinase 2 mitogen-activated protein kinase phosphorylation and regulation of activity of PDE4 cyclic adenosine monophosphate-specific phosphodiesterases. Methods Mol Biol 307:225-237, 2005.
73. Oki N, Takahashi SI, Hidaka H, Conti M. Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation. J Biol Chem 275:10831-10837, 2000.
74. Reed TM, Repaske DR, Snyder GL, Greengard P, Vorhees CV. Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. J Neurosci 22:5188-5197, 2002.
75. Masciarelli S, Horner K, Liu C, Park SH, Hinckley M, Hockman S, Nedachi T, Jin C, Conti M, Manganiello V. Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J Clin Invest 114:196-205, 2004.
76. Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux MP, Jin SL, Conti M. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol 173:7531-7538, 2004.
77. Jin SL, Latour AM, Conti M. Generation of PDE4 knockout mice by gene targeting. Methods Mol Biol 307:191-210, 2005.
78. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 99:7628-7633, 2002.
79. Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, Conti M. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci U S A 96:11998-12003, 1999.
80. Mehats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, Conti M. PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J 17:1831-1841, 2003.
81. Hansen G, Jin S, Umetsu DT, Conti M. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci U S A 97:6751-6756, 2000.
82. Ma D, Wu P, Egan RW, Billah MM, Wang P. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol 55:50-57, 1999.
83. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 56:170-174, 1999.
84. Jin SL, Lan L, Zoudilova M, Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175:1523-1531, 2005.
85. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL, Conti M, Marks AR. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123:25-35, 2005.
86. Butcher RW, Sutherland EW. Adenosine 3′,5′-phosphate in biological materials. I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine. J Biol Chem 237:1244-1250, 1962.
87. Dousa T, Rychlik I. Adenyl cyclase and adenosine 3′,5′-cyclic phosphate phosphodiesterase in the receptor tissues of neurohypophysial hormones. Life Sci 7:1039-1044, 1968.
88. Dousa T, Rychlik I. The metabolism of adenosine 3′,5′-cyclic phosphate. II. Some properties of adenosine-3′,5′-cyclic-phosphate phosphodiesterase from the rat kidney. Biochim Biophys Acta 204: 10-17, 1970.
89. Thompson WJ, Epstein PM, Strada SJ. Purification and characterization of high-affinity cyclic adenosine monophosphate phosphodiesterase from dog kidney. Biochemistry 18:5228-5237, 1979.
90. Nicholson CD, Challiss RAJ, Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. TIPS 12:19-27, 1991.
91. Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci Rev 11:150-155, 1990.
92. Shingleton BJ. Eye injuries. N Engl J Med 325:408-413, 1991.
93. Torres VE, Hui YSF, Shah SV, Northrup TE, Dousa TP. Cyclic nucleotide phosphodiesterases in glomeruli of rat renal cortex. Kidney Int 14:444-451, 1978.
94. Matousovic K, Tsuboi Y, Walker H, Grande JP, Dousa TP. Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid. J Lab Clin Med 130:487-495, 1997.
95. Chini CCS, Chini EN, Williams JM, Matousovic K, Dousa TP. Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isozyme type IV. Kidney Int 46:28-36, 1994.
96. Jackson BA, Edwards RM, Valtin H, Dousa TP. Cellular action of vasopressin in medullary tubules of mice with hereditary nephrogenic diabetes insipidus. J Clin Invest 66:110-122, 1980.
97. Homma S, Gapstur SM, Coffey A, Valtin H, Dousa TP. Role of cAMP-phosphodiesterase isozymes in pathogenesis of murine nephrogenic diabetes insipidus. Am J Physiol 261:F345-F353, 1991.
98. Takeda S, Lin C-T, Morgano PG, McIntrye SJ, Dousa TP. High activity of low-Michaelis-Menten constant 3′,5′-cyclic adenosine monophosphate-phosphodiesterase isozymes in renal inner medulla of mice with hereditary nephrogenic diabetes insipidus. Endocrinology 129:287-294, 1991.
99. Lee EY, Humphreys MH. Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Am J Physiol 271:F3-F6, 1996.
100. Valentin JP, Qiu C, Muldowney WP, Ying WZ, Gardner DG, Humphreys MH. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest 90: 1302-1312, 1992.
101. Schoeffter P, Lugnier C, Travo C, Stoclet JC. A comparison of cyclic AMP signaling system in rat aortic myocytes in primary culture and aorta. Lab Invest 61:177-182, 1989.
102. Tsuboi Y, Shankland SJ, Grande JP, Walker HJ, Johnson RJ, Dousa TP. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. J Clin Invest 98:262-270, 1996.
103. Dousa T. Glomerular metabolism. In: Seldin D, Giebisch G, Eds. The Kidney: Physiology and pathophysiology. New York: Raven Press, pp645-667, 1985.
104. Johnson RJ. The glomerular response to injury: progression or resolution? Kidney Int 45:1769-1782, 1994.
105. Matousovic K, Grande JP, Chini CCS, Chini EN, Dousa TP. Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. J Clin Invest 96:401-410, 1995.
106. D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 67:353-366, 1997.
107. Sevetson BR, Kong X, Lawrence JC. Increasing cAMP attenuates activation of mitogen activated protein kinase. Proc Natl Acad Sci U S A 90:10305-10309, 1993.
108. Hafner S, Adler HS, Mischak H, Janosch P, Heidecker G, Wolfman A, Pippig S, Lohse M, Ueffing M, Kolch W. Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol 14:6696-6703, 1994.
109. Yee WM, Worley PF. Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals. Mol Cell Biol 17:921-933, 1997.
110. Danoff TM. Chemokines in interstitial injury. Kidney Int 53:1807-1808, 1998.
111. Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 47:1546-1557, 1995.
112. Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, Gutierrez-Ramos JC. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 185:1371-1380, 1997.
113. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda SI, Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukaida N, Naito T, Matsushima K, Yokoyama H. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 58:1492-1499, 2000.
114. Stahl RA, Thaiss F, Disser M, Helmchen U, Hora K, Schlondorff D. Increased expression of monocyte chemoattractant protein-1 in antithymocyte antibody-induced glomerulonephritis. Kidney Int 44:1036-1047, 1993.
115. Whitman M. Smads and early developmental signaling by the TGF-β superfamily. Genes Dev 12:2445-2462, 1998.
116. Schiffer M, von Gersdorff G, Bitzer M, Susztak K, Bottinger EP. Smad proteins and transforming growth factor-β signaling. Kidney Int 77(Suppl):S45-S52, 2000.
117. Chini C, Grande J, Thompson M, Walker H, Dousa T. Isoenzymes of cyclic-3′,5′-nucleotide phosphodiesterases (PDE) in rat glomerular epithelial cells (GEC) and mesangial cells (MC). (abstract). FASEB J 8:A83, 1994.
118. Yamaki M, McIntyre S, Rassier ME, Schwartz JH, Dousa TP. Cyclic 3′,5′-nucleotide diesterases in dynamics of cAMP and cGMP in rat collecting duct cells. Am J Physiol 262:F957-F964, 1992.
119. Rassier ME, McIntyre SJ, Yamaki M, Takeda S, Lin J-T, Dousa TP. Isozymes of cyclic-3′,5′-nucleotide phosphodiesterases in renal epithelial LLC-PK1 cells. Kidney Int 41:88-99, 1992.
120. Yamaki M, McIntyre S, Murphy JM, Swinnen JV, Conti M, Dousa TP. ADH resistance of LLC-PK1 cells caused by overexpression of cAMP-phosphodiesterase type-IV. Kidney Int 43:1286-1297, 1993.
121. Bouley R, Breton S, Sun T, McLaughlin M, Nsumu NN, Lin HY, Ausiello DA, Brown D. Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells. J Clin Invest 106:1115-1126, 2000.
122. Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham J. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 20:703-709, 1997.
123. Grantham JJ. Renal cell proliferation and the two faces of cyclic adenosine monophosphate. J Lab Clin Med 130:459-460, 1997.
124. Mangoo-Karim R, Uchic M, Lechene C, Grantham J. Renal epithelial cyst formation and enlargement in vitro: dependence on cAMP. Proc Natl Acad Sci U S A 86:6007-6011, 1989.
125. Cheng J, Thompson MA, Walker HJ, Gray CE, Warner GM, Zhou W, Grande JP. Lixazinone stimulates mitogenesis of Madin-Darby canine kidney cells. Exp Biol Med (Maywood) 231:288-295, 2006.
126. Hewitson TD, Martic M, Kelynack KJ, Pedagogos E, Becker GJ. Pentoxifylline reduces in vitro renal myofibroblast proliferation and collagen secretion. Am J Nephrol 20:82-88, 2000.
127. Hewitson TD, Tait MG, Kelynack KJ, Martic M, Becker GJ. Dipyridamole inhibits in vitro renal fibroblast proliferation and collagen synthesis. J Lab Clin Med 140:199-208, 2002.
128. Chen YM, Chien CT, Hu-Tsai MI, Wu KD, Tsai CC, Wu MS, Tsai TJ. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 56:932-943, 1999.
129. Tam FW, Smith J, Agarwal S, Karkar AM, Morel D, Thompson EM, Pusey CD. Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. Nephron 84:58-66, 2000.
130. Valentin JP, Ying WZ, Sechi LA, Ling KT, Qiu C, Couser WG, Humphreys MH. Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann nephritis. J Am Soc Nephrol 7:582-593, 1996.
131. Okusa MD, Linden J, Huang L, Rosin DL, Smith DF, Sullivan G. Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney Int 59:2114-2125, 2001.
132. Okusa MD, Linden J, MacDonald T, Huang L. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol 277:F404-F412, 1999.
133. Begany DP, Carcillo JA, Herzer WA, Mi Z, Jackson EK. Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure. J Pharmacol Exp Ther 278:37-41, 1996.
134. Carcillo JA, Herzer WA, Mi Z, Thomas NJ, Jackson EK. Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine. J Pharmacol Exp Ther 279:1197-1204, 1996.
135. Guan Z, Miller SB, Greenwald JE. Zaprinast accelerates recovery from established acute renal failure in the rat. Kidney Int 47:1569-1575, 1995.
136. Harris AL, Lemp BM, Bentley RG, Perrone MH, Hamel LT, Silver PJ. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J Pharmacol Exp Ther 249:394-400, 1989.
137. Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol 13:2916-2929, 2002.
138. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Espinoza F, Pons H, Vaziri ND. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int 68: 2131-2142, 2005.
139. Hindmarch I, Fuchs HH, Erzigkeit H. Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 6:31-43, 1991.
140. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Burger A, Hatzelmann A, Tenor H, Schudt C, Krull M, Schutte H, Hippenstiel S, Suttorp N. Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 105:3569-3576, 2005.
141. Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47:1081-1092, 2004.
142. Cruickshank JM. Phosphodiesterase III inhibitors: long-term risks and short-term benefits. Cardiovasc Drugs Ther 7:655-660, 1993.
143. Shipley JB, Tolman D, Hastillo A, Hess ML. Milrinone: basic and clinical pharmacology and acute and chronic management. Am J Med Sci 311:286-291, 1996.
144. Carson P. Pharmacologic treatment of congestive heart failure. Clin Cardiol 19:271-277, 1996.
145. Liu Y, Shakur Y, Yoshitake M, Kambayashi J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 19:369-386, 2001.
146. Ochiai M, Isshiki T, Takeshita S, Eto K, Toyoizumi H, Sato T, Miyashita H. Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen. Am J Cardiol 79:1471-1474, 1997.
147. Wagner RS, Smith CJ, Taylor AM, Rhoades RA. Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther 282:1650-1657, 1997.
148. Giembycz MA. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem Pharm 43:2041-2051, 1992.
149. Giembycz MA. Phosphodiesterase 4 and tolerance to beta 2-adrenoceptor agonists in asthma. Trends Pharmacol Sci 17:331-336, 1996.
150. Torphy TJ, Undem BJ. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46:512-523, 1991.
151. Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, Torphy TJ, Barnette MS. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 128: 1393-1398, 1999.
152. Overstreet DH, Double K, Schiller GD. Antidepressant effects of rolipram in a genetic animal model of depression: cholinergic supersensitivity and weight gain. Pharmacol Biochem Behav 34: 691-696, 1989.
153. Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, Schratzer M, Troisfontaines B, von Frenckell R, Wachtel H. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized
154. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmuller A, Fontana A, Dichgans J, Martin R. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1:244-248, 1995.
155. Pinsky D, Oz M, Liao H, Morris S, Brett J, Sciacca R, Karakurum M, Van Lookeren Campagne M, Platt J, Nowygrod R, Koga S, Stern D. Restoration of the cAMP second messenger pathway enhances cardiac preservation for transplantation in a heterotopic rat model. J Clin Invest 92:2994-3002, 1993.
156. Naka Y, Roy DK, Liao H, Chowdhury NC, Michler RE, Oz MC, Pinsky DJ. cAMP-mediated vascular protection in an orthotopic rat lung transplant model. Insights into the mechanism of action of prostaglandin E1 to improve lung preservation. Circ Res 79:773-783, 1996.
157. Dousa MK, Moore SB, Ploeger NA, DeGoey SR, Dousa TP. Antagonists of cyclic nucleotide phosphodiesterase (PDE) isozymes PDE 3 and PDE 4 suppress lymphoblastic response to HLA class II alloantigens: a potential novel approach to preventing allograft rejection? Clin Nephrol 47:187-189, 1997.
158. Takahashi T, Kanda T, Inoue M, Suzuki T, Kobayashi I, Kodama K, Nagai R. A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Life Sci 59:PL371-377, 1996.
159. Braner DA, Fineman JR, Chang R, Soifer SJ. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol 264:H252-H258, 1993.
160. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78:257-261, 1996.
161. Pinsky DJ, Naka Y, Chowdhury NC, Liao H, Oz MC, Michler RE, Kubaszewski E, Malinski T, Stern DM. The nitric oxide/cyclic GMP pathway in organ transplantation: critical role in successful lung preservation. Proc Natl Acad Sci U S A 91:12086-12090, 1994.
162. Prickaerts J, Sik A, van Staveren WC, Koopmans G, Steinbusch HW, van der Staay FJ, de Vente J, Blokland A. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem Int 45:915-928, 2004.